M (continued)
- MPC-6827
- mRNA-derived prostate cancer vaccine CV9103
- MS Contin
- MSir
- mTOR kinase inhibitor AZD2014
- mTOR kinase inhibitor AZD8055
- mTOR kinase inhibitor OSI-027
- MUC-1 antigen
- MUC-1 peptide vaccine
- MUC1 peptide-poly-ICLC adjuvant vaccine
- MUC1-KLH conjugate vaccine
- MUC1-KLH vaccine / QS21
- Mucomyst
- multi-epitope melanoma peptide vaccine
- MultiHance
- MultiHance
- multikinase inhibitor AT9283
- multikinase inhibitor SAR103168
- MultiStem
- multitargeted receptor tyrosine kinase inhibitor MP470
- multitargeted tyrosine kinase inhibitor AP24534
- multitargeted tyrosine kinase inhibitor BIBF 1120
- multitargeted tyrosine kinase inhibitor DCC-2036
- multitargeted tyrosine kinase inhibitor JNJ-26483327
- multitargeted tyrosine kinase inhibitor MGCD265
M (continued)
- multitargeted tyrosine kinase inhibitor PLX3397
- multivitamin
- mureletecan
- murine TYRP2 plasmid DNA vaccine
- muromonab-CD3
- MUSE
- Mustargen
- Mutamycin
- mutant p53 peptide pulsed dendritic cell vaccine
- MVA-FCU1 TG4023
- MVA-PSA-PAP prostate cancer vaccine
- Mycelex
- Mycelex Troche
- mycobacterial cell wall-DNA complex
- Mycobacterium w
- Mycobutin
- mycophenolate mofetil
- Myleran
- Mylosar
- Mylotarg
- Mylovenge
- Myochrysine
N
- N-methylformamide
- N-phosphonacetyl-L-aspartate
- NA17-A antigen